Dogwood Therapeutics, INC 10-Q quarterly reports

Dogwood Therapeutics, Inc. filed its Q2 2026 10-Q, detailing increased operating expenses, a significant impairment charge, and highlighting substantial doubt about its ability to continue as a going concern.

Dogwood Therapeutics reports increased R&D and G&A expenses in Q1 2026, with cash reserves projected to fund operations into Q4 2026, necessitating future financing.

Dogwood Therapeutics, a pre-revenue biopharmaceutical company, reported significant net losses for Q3 2025 and indicated a need for additional financing to fund operations beyond Q1 2026.

Dogwood Therapeutics, a pre-revenue biopharmaceutical company, reported a significant increase in net loss and operating expenses, raising substantial doubt about its ability to continue as a going concern.

Dogwood Therapeutics announces its Q1 2025 financial results, highlighting advancements in its Halneuron clinical trial and addressing Nasdaq compliance.

Dogwood Therapeutics, formerly Virios Therapeutics, announced its Q3 2024 financial results, the acquisition of Pharmagesic, and a $16.5 million loan, while also highlighting its pipeline progress.

Virios Therapeutics reported its financial results for the second quarter of 2024, highlighting ongoing clinical development and financial challenges.

Virios Therapeutics reported a net loss of $1.3 million for the first quarter of 2024 and is actively seeking partnerships and funding to advance its clinical programs.